Genzyme gets broad approval for Seprafilm
This article was originally published in Clinica
US biotechnology company Genzyme has received unexpectedly broad approval for its surgical adhesion preventative, Seprafilm. The FDA has granted approval for the bioresorbable membrane to be used in any open abdominal or pelvic surgery, despite the lack of any long-term data showing a reduction in complications. Two clinical trials have shown that Seprafilm reduces adhesion formation by about 50%.
You may also be interested in...
With its US/Mexico Phase III trial delayed due to manufacturing questions, Novavax has aligned its UK study with FDA guidance. It hopes for interim data from that study during Q1 2021.
The companies think they can build out the indications for zuranalone and SAGE-324 faster and more broadly and commercialize the drugs more effectively as partners.